
Benzinga Pro data, Bicycle Therapeutics (NASDAQ:BCYC) reported Q1 sales of $3.86 million. Earnings fell to a loss of $27.56 million, resulting in a 52.82% decrease from last quarter. Bicycle Therapeutics collected $3.77 million in revenue during Q4, but reported earnings showed a $18.04 million loss.